Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate 10 mg in 10 ml - milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are contraindicated in patients who are hypersensitive to it.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

horizon therapeutics usa, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 20 mg in 1 g - pennsaid is indicated for the treatment of the pain of osteoarthritis of the knee(s). pennsaid is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ] risk summary use of nsaids, including pennsaid, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of pennsaid use between about 20 and 30 weeks of gestation, and avoid pennsaid use at about 30 weeks of ge

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. atrovent hfa is contraindicated in the following conditions [see warnings and precautions (5.2) ]. - hypersensitivity to ipratropium bromide or other atrovent hfa components - hypersensitivity to atropine or any of its derivatives risk summary ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . there is limited experience with ipratropium bromide use in pregnant women. published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. based on animal reproduction studies, no evidence of structural alteration

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

physicians total care, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 108 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relatio

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

h.j. harkins company, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 108 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relatio

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

remedyrepack inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - proair hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. proair hfa inhalation aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. proair hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to albuterol and any other proair hfa inhalation aerosol components. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate [see warnings and precautions (5.6) ] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medications during pregnancy. for more information, contact the mothers to baby pregnancy studies conducted by the organization of teratology information specialists at 1-877-311-8972 or visit http://mothert

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

janssen biotech, inc. - amivantamab (unii: 0jsr7z0nb6) (amivantamab - unii:0jsr7z0nb6) - rybrevant is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutations, as detected by an fda-approved test [see dosage and administration (2.2)] . rybrevant is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 20 insertion mutations, as detected by an fda-approved test [see dosage and administration (2.2)] , whose disease has progressed on or after platinum-based chemotherapy. none. risk summary based on the mechanism of action and findings in animal models, rybrevant can cause fetal harm when administered to a pregnant woman. there are no available data on the use of rybrevant in pregnant women or animal data to assess the risk of rybrevant in pregnancy. disruption or depletion of egfr in animal models resulted in impairment of embryo-fetal development including effects on placental, lung, cardiac, skin, and neural development. the absence of egfr or met signaling has resulted in embryo lethality, malformations, and post-natal death in animals ( see data ) . advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data no animal studies have been conducted to evaluate the effects of amivantamab-vmjw on reproduction and fetal development; however, based on its mechanism of action, rybrevant can cause fetal harm or developmental anomalies. in mice, egfr is critically important in reproductive and developmental processes including blastocyst implantation, placental development, and embryo-fetal/postnatal survival and development. reduction or elimination of embryo-fetal or maternal egfr signaling can prevent implantation, can cause embryo-fetal loss during various stages of gestation (through effects on placental development) and can cause developmental anomalies and early death in surviving fetuses. adverse developmental outcomes were observed in multiple organs in embryos/neonates of mice with disrupted egfr signaling. similarly, knock out of met or its ligand hgf was embryonic lethal due to severe defects in placental development, and fetuses displayed defects in muscle development in multiple organs. human igg1 is known to cross the placenta; therefore, amivantamab-vmjw has the potential to be transmitted from the mother to the developing fetus. risk summary there are no data on the presence of amivantamab-vmjw in human milk, the effects on the breastfed child or on milk production. because of the potential for serious adverse reactions from rybrevant in breast-fed children, advise women not to breast-feed during treatment with rybrevant and for 3 months after the last dose. rybrevant can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. pregnancy testing verify pregnancy status of females of reproductive potential prior to initiating rybrevant. contraception females advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of rybrevant. the safety and efficacy of rybrevant have not been established in pediatric patients. of the 151 patients with locally advanced or metastatic nsclc treated with rybrevant in combination with carboplatin and pemetrexed in the papillon study, 37% were ≥65 years of age and 8% were ≥75 years of age. of the 302 patients with locally advanced or metastatic nsclc treated with rybrevant as a single agent in the chrysalis study, 39% were ≥65 years of age and 11% were ≥75 years of age. no clinically important differences in safety or efficacy were observed between patients who were ≥65 years of age and younger patients.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - 1.1 bronchospasm proair hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 exercise-induced bronchospasm proair hfa inhalation aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. proair hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to albuterol and any other proair hfa inhalation aerosol components. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate [see warnings and precautions (5.6)]. 8.1 pregnancy teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies of proair hfa inhalation aerosol or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offsprin

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

king bio inc. - actaea, aesculus hipp, arnica, bellis, bryonia, calc carb, calc fluor, causticum, cimicifuga, formicum acidum,hypericum, ledum, lithium carb, mag phos, phos, phytolacca, pulsatilla, rhododendron, rhus tox, ruta, salicylicum ac, sepia, zinc met., equal  volumes of each hpus ingredient in 10x, 30x,  100x, 1lm, 2lm, 3lm, 5lm potencies. , , reference image: arthritis.jpg - for temporary relief of symptoms associated with arthritic pain: rheumatic pain, stiff and swollen joints pain in any joint reference image: arthritis.jpg uses for temporary relief of:  joint inflammation aching joints rheumatic pain stiff and swollen joints pain in any joint refernce image: arthritis.jpg

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

king bio inc. - aesculus hipp, arnica, bellis, bryonia, calc carb, calc fluor, cimicifuga, cobaltum met, gnaphalium poly, hypericum, kali carb, kali phos, mag phos, oxalicum ac, phos, rhus tox, ruta, zinc met., equal volumes of each hpus ingredient in 10x, 30x, 100x, 1lm, 2lm, 3lm, 5lm potencies., reference image: back.jpg - for temporary relief of symptoms: back pain, sprains and strains, acute pain and injury, muscle cramps, tension and stiffness. reference image: back.jpg for temporary relief of symptoms: back pain sprains and strains acute pain and injury muscle cramps tension and stiffness reference image: back.jpg